Among these, RENT3B had a poor prognosis in six cancer types: blood tumor (OS: HR = 2.43), brain cancer (OS: HR = 1.77), breast cancer (RFS: HR = 1.85; DSS: HR = 2.94; DMFS: HR = 1.95), colorectal cancer (OS: HR = 1.83; DSS: HR = 1.86), lung cancer (OS: HR = 1.92), and soft tissue tumor (DRFS: HR = 2.54). This evidence concerns the gene UPF3B and lung carcinoma.